Projected Income Statement: Beam Therapeutics Inc.

Forecast Balance Sheet: Beam Therapeutics Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - -292 -960 -1,078 -1,190 -786 -376 -
Change - - -428.77% -212.29% -210.39% -166.06% -147.84% -
Announcement Date 3/30/20 3/15/21 2/28/22 2/28/23 2/27/24 - - -
1USD in Million
Estimates

Cash Flow Forecast: Beam Therapeutics Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
CAPEX 1 12.52 16.36 46.81 48.95 33.73 28.85 31.36 32.22
Change - 30.67% 186.18% 4.57% -31.09% -14.47% 8.7% 2.76%
Free Cash Flow (FCF) 1 -84.52 -112.1 -113.1 -26.42 -182.9 -348.3 -337.8 -295.2
Change - 32.63% 0.88% -76.63% 592.28% 90.4% -3% -12.61%
Announcement Date 3/30/20 3/15/21 2/28/22 2/28/23 2/27/24 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Beam Therapeutics Inc.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026

Profitability

        
EBITDA Margin (%) - - -742.64% -532.39% -41.43% -770.72% -740.95% -598.04%
EBIT Margin (%) -417,522.22% -553,166.67% -757.01% -555.61% -46.73% -821.6% -796.79% -701.62%
EBT Margin (%) -435,144.44% -810,800% -714.91% -427.08% -34.73% -767.96% -753.98% -663.15%
Net margin (%) -505,777.78% -816,120.83% -714.91% -474.54% -35.09% -770.16% -758.29% -657.9%
FCF / Net Income (%) -469,561.11% -467,075% -218.11% -43.37% -48.43% -679.45% -609.13% -443.1%

Profitability

        
ROA -56.35% -64.45% -38.49% -20.53% -11.69% -30.3% -35.8% -
ROE - -881.16% -69.13% -37.06% -15.46% -50.03% -68.65% -80.25%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 69,544.44% 68,154.17% 90.29% 80.35% 8.93% 56.28% 56.54% 48.36%
CAPEX / EBITDA (%) - - -12.16% -15.09% -21.56% -7.3% -7.63% -8.09%
CAPEX / FCF (%) -14.81% -14.59% -41.4% -185.25% -18.44% -8.28% -9.28% -10.91%

Items per share

        
Cash flow per share 1 - - -1.032 0.3217 -1.934 -3.831 -3.561 -
Change - - - -131.18% -701.12% 98.09% 92.95% -
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 -3.917 5.255 12.87 10.7 12.72 10.65 8.87 -
Change - -234.14% 144.97% -16.91% 18.93% -16.27% 83.29% -
EPS 1 -2.489 -4.19 -5.77 -4.13 -1.72 -4.692 -4.632 -4.531
Change - 68.33% 37.71% -28.42% -58.35% 172.81% 98.71% 97.82%
Nbr of stocks (in thousands) - 56,474 66,849 68,821 79,326 78,909 78,909 78,909
Announcement Date 3/30/20 3/15/21 2/28/22 2/28/23 2/27/24 - - -
1USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
30.32USD
Average target price
50.07USD
Spread / Average Target
+65.14%
Consensus
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Financials Beam Therapeutics Inc.